(Q34355963)

English

Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Andrew J Bradley

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Alan J Lenox-Smith

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

5 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

740-758

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

The number needed to treat: a clinically useful measure of treatment effect

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

What can we learn from Chinese randomized controlled trials? A systematic review and meta-analysis of Chinese venlafaxine studies

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Accounting for dropout bias using mixed-effects models.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Critical evaluation of mixed treatment comparison meta-analyses using examples assessing antidepressants and opioid detoxification treatments.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Pharmacology and pharmacokinetics of milnacipran

1 reference

https://api.crossref.org/works/10.1177%2F0269881113494937

21 January 2018

Identifiers

10.1177/0269881113494937

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34355963&oldid=1548004317"